BTIG Maintains Buy Rating for Castle Biosciences: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
BTIG maintains its Buy rating for Castle Biosciences (NASDAQ:CSTL) but lowers its price target from $38.00 to $30.00. Shares of CSTL are trading down 1.98% at $13.40 per share.

June 15, 2023 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG maintains Buy rating for Castle Biosciences (NASDAQ:CSTL) but lowers price target from $38.00 to $30.00. CSTL shares are trading down 1.98% at $13.40.
The lowered price target from BTIG may cause short-term uncertainty, but the maintained Buy rating indicates a positive outlook for Castle Biosciences. The potential 123.88% increase from the current share price to the new target price suggests a bullish sentiment for the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100